The two- day event covered several topics issues related to formulation development and drug delivery
The second day of FDD Conclave 2018 saw experts and veterans of pharma formulation development and drug delivery sector continued with their discussions on industry-relevant issues.
The first discussion for the day began with a presentation on Vaccine Delivery- emerging opportunity by Sukhjeet Singh, Senior VP R&D, Panacea Biotec. He briefed the audience on the challenges, opportunities and market potential in the vaccine delivery sector. He says, “The market potential for vaccine should be much higher than pharma. As the morality rate in India is high, the field is gathering competitors and a lot of players are entering in this segment.” Touching upon the regulatory aspects in this sector, he also pointed out that as the regulatory push in vaccines is less from US FDA, the development of vaccines are not happening on time. He further spoke on novel vaccine delivery systems (NVDS); Panacea’s contribution to the industry and their product EasySix.
Next was a panel discussion on the topic, ‘Product Development through Integrated Project Management’. Moderated by Dr Amit Biswas, Executive Vice President-Integrated Product Development, DRL,the panel had other eminent panelists such as Subhadra Ummeda Group Head – Business Analytics Novartis, Hyderabad; Dr Shirish Kulkarni, Sr VP-R&D, Sun Pharma, Sandhya Shenoy, AVP- R&D, FDC, and Dr Sumedha Nadkar, Site Head and Senior Director, Perrigo Labs India. The panelists addressed vital issues related to the integrated product development from inception too Commercialisation; Horizontally and vertically integrated project management for global product development; Functional excellence in optimum resource utilisation; and role of data analytics in integrated project management.
Suresh Pareek, Managing Director, Ideal Cures also gave a presentation on Ideal Cures Documented Solutions. In his presentation, he briefed the audience on the product offered by Ideal Cures and how his company can be a very valuable partner to pharma companies in their path to progress.
The last panel discussion was on 505(b)2: Avenues for Development. The panel was moderated by life time achievement award winner of FDD Conclave 2017, Dr Himadri Sen, Chairman, Steerlife. The other panelists in this session were Dr Rajeev Singh Raghuvanshi, Senior Vice-President and Global Head-CMC, Dr Reddy’s Laboratories; Dr Girish Jain, Consultant; and Indu Bhushan, Chief Technology Officer, Steerlife. The panel had an in depth discussion on strategies to move up the value chain through innovation and R&D. The panelists shared their insights on smarter regulatory pathways; extending exclusivity beyond norms for certain unmet medical needs and robust IP protections; moving from simple to complex strategies for better expected market realisation; and complex generics for 505(b)2 consideration.
The last session at FDD Conclave was on Innovation in FDD: The way forward for India Pharma Inc by Dr Amit Biswas, Executive Vice President-Integrated Product Development, DRL. In this session, he highlighted how the sector is undergoing a major transformation and urged the Indian pharma industry to gear up for Pharma 4.0. Thus, this year’s FDD Conclave offered a lot of food for thought for the delegates who were part of the event.
swati.rana@expressindia.com